All In Biotech

Drug Trial Radar · NCT07826689

A Phase 1/2a Study of Oral PRO-1562 in Healthy Subjects and Patients With Relapsing Multiple Sclerosis

A Randomized, Double-Blind, Placebo-Controlled Phase 1/2a Trial of PRO-1562 in Healthy Adults and Adults With Multiple Sclerosis and Chronic Optic Neuropathy

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Dec 2028

Study completion Feb 2029

Sponsor

Lead sponsor
Progentos TherapeuticsIndustry
Sponsor type
Industry
First posted
Sep 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Phase 1 will test single oral doses of PRO-1562 in healthy adult subjects to characterize the safety and the amount of drug that is absorbed into the body. Some subjects will have lumbar punctures performed to measure the amount of drug that crosses the blood-brain barrier since that is the site of drug activity. Phase 2a will be a 6-month trial to test the ability of once monthly dosing of PRO-1562 to promote remyelination of the CNS and provide clinical benefit to adult patients with relapsing multiple sclerosis (RMS) who also have long-term vision problems diagnosed as chronic optic neuropathy. The benefits of remyelination will be measured using tests of visual acuity, speed of optic nerve conduction signals, and clinical assessments of cognitive and motor function. PRO-1562 will be added on to a stable regimen of MS disease modifying therapy.

Conditions

  • Multiple Sclerosis

Interventions

  • PRO-1562 Oral CapsulesDrug

    Oral, CNS-penetrant small molecule designed to induce remyelination

  • Placebo Oral CapsuleDrug

    Placebo filled capsules that look like the active intervention

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 Incidence of ≥Grade 2 treatment-emergent adverse eventsTime frame: From enrollment until 7 days post dose
  2. Phase 2 Change from baseline P100 VEP latencyTime frame: From enrollment until the end of 6 months of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CMAX Clinical Research

    Adelaide, South Australia, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.